por Fisio » Mié, 04 Sep 2013, 11:44
por Antonio » Jue, 10 Oct 2013, 17:13
por Fisio » Vie, 11 Oct 2013, 12:43
por Valanor » Vie, 11 Oct 2013, 14:19
por Antonio » Vie, 11 Oct 2013, 18:29
por Fisio » Vie, 11 Oct 2013, 19:25
Antonio escribió:El B-Right era lo único que tenía más claro, yo lo uso frecuentemente. Mi objetivo es detenerle ese deterioro y potenciarle la memoria, ya que pierde "el hilo" de las cosas a menudo, se que es cuestión de ir probando cosillas hasta que ella note algo, o se encuentre más atenta, alerta..
Comienzo por Jarrow EPA/DHA (2 caps/día) + Jarrow B-Right (1 caps/día) + Jarrow Citicolina (2 caps/día)
¿añado también huperzina A?
por Antonio » Vie, 11 Oct 2013, 21:47
por Fisio » Sab, 12 Oct 2013, 13:21
Valanor escribió:Tambien tomar te blanco a diario le ayudaria, por el tema de la l-teanina.
A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study.
Park SK, Jung IC, Lee WK, Lee YS, Park HK, Go HJ, Kim K, Lim NK, Hong JT, Ly SY, Rho SS.
LG Household and Health Care Co., Ltd., Daejeon, Korea.
A combination of green tea extract and l-theanine (LGNC-07) has been reported to have beneficial effects on cognition in animal studies. In this randomized, double-blind, placebo-controlled study, the effect of LGNC-07 on memory and attention in subjects with mild cognitive impairment (MCI) was investigated. Ninety-one MCI subjects whose Mini Mental State Examination-K (MMSE-K) scores were between 21 and 26 and who were in either stage 2 or 3 on the Global Deterioration Scale were enrolled in this study. The treatment group (13 men, 32 women; 57.58 ± 9.45 years) took 1,680 mg of LGNC-07, and the placebo group (12 men, 34 women; 56.28 ± 9.92 years) received an equivalent amount of maltodextrin and lactose for 16 weeks. Neuropsychological tests (Rey-Kim memory test and Stroop color-word test) and electroencephalography were conducted to evaluate the effect of LGNC-07 on memory and attention. Further analyses were stratified by baseline severity to evaluate treatment response on the degree of impairment (MMSE-K 21-23 and 24-26). LGNC-07 led to improvements in memory by marginally increasing delayed recognition in the Rey-Kim memory test (P = .0572). Stratified analyses showed that LGNC-07 improved memory and selective attention by significantly increasing the Rey-Kim memory quotient and word reading in the subjects with MMSE-K scores of 21-23 (LGNC-07, n = 11; placebo, n = 9). Electroencephalograms were recorded in 24 randomly selected subjects hourly for 3 hours in eye-open, eye-closed, and reading states after a single dose of LGNC-07 (LGNC-07, n = 12; placebo, n = 12). Brain theta waves, an indicator of cognitive alertness, were increased significantly in the temporal, frontal, parietal, and occipital areas after 3 hours in the eye-open and reading states. Therefore, this study suggests that LGNC-07 has potential as an intervention for cognitive improvement.
Theanine prevents memory impairment induced by repeated cerebral ischemia in rats.
Egashira N, Ishigami N, Pu F, Mishima K, Iwasaki K, Orito K, Oishi R, Fujiwara M.
Department of Pharmacy, Kyushu University Hospital, Fukuoka 812-8582, Japan. firstname.lastname@example.org
The present study investigated the neuroprotective effect of gamma-glutamylethylamide (theanine), a component Japanese green tea (Camellia sinensis), on memory impairment induced by twice-repeated cerebral ischemia in rats. Theanine was injected i.p. immediately after the first occlusion. Theanine (0.3 and 1 mg/kg) significantly prevented the impairment of spatial memory in rats subjected to repeated cerebral ischemia, 7 days after the second reperfusion. Moreover, theanine (1 mg/kg) significantly inhibited the decrease in the number of surviving cells in the hippocampal CA1 field in the same rats. These results suggest that theanine prevents memory impairment induced by repeated cerebral ischemia, in part by protecting against neuronal cell death, and that it might be useful for preventing cerebrovascular disease.
l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways.
Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, Nam SY, Yun YW, Han SB, Oh KW, Hong JT.
College of Pharmacy and CBITRC, Chungbuk National University, Cheongju, Chungbuk 361-763, Korea.
Amyloid beta (Abeta)-induced neurotoxicity is a major pathological mechanism of Alzheimer disease (AD). In this study, we investigated the inhibitory effect of l-theanine, a component of green tea (Camellia sinensis), on Abeta(1-42)-induced neuronal cell death and memory impairment. Oral treatment of l-theanine (2 and 4 mg/kg) for 5 weeks in the drinking water of mice, followed by injection of Abeta(1-42) (2 microg/mouse, icv), significantly attenuated Abeta(1-42)-induced memory impairment. Furthermore, l-theanine reduced Abeta(1-42) levels and the accompanying Abeta(1-42)-induced neuronal cell death in the cortex and hippocampus of the brain. Moreover, l-theanine inhibited Abeta(1-42)-induced extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase as well as the activity of nuclear factor kappaB (NF-kappaB). l-Theanine also significantly reduced oxidative protein and lipid damage and the elevation of glutathione levels in the brain. These data suggest that the positive effects of l-theanine on memory may be mediated by suppression of ERK/p38 and NF-kappaB as well as the reduction of macromolecular oxidative damage. Thus, l-theanine may be useful in the prevention and treatment of AD.
por dr.z » Mié, 16 Oct 2013, 20:16
Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice
HAYWARD, Calif., May 16, 2013 /PRNewswire/ -- Scientists at the Center for Learning and Memory, Tsinghua University, Beijing, and the California-based biopharmaceutical company Magceutics, Inc. (http://www.magceutics.com) have demonstrated a novel therapy for reversing memory decline in mice with Alzheimer's Disease. By increasing brain magnesium levels, they find significant cognitive improvement in advanced stage AD mice. The study is the first to demonstrate a mechanism for reversing cognitive decline for advanced stage AD mice, and is also the first to show an effective long term treatment for early stage AD mice.
"We found that the elevation of brain magnesium can prevent cognitive decline in Alzheimer's Disease model mice," explained Magceutics founder Guosong Liu, a professor at Tsinghua University and senior investigator on the study. The report, which appeared online May 8th in the Journal of Neuroscience, shows that a newly developed magnesium compound known as Magtein™ (Magnesium-L Threonate) can prevent cognitive impairment when administered to mice with early stage AD. The treatment was shown to remain effective for at least 16 months. Additionally, Magtein significantly improved memory and cognition when given to advanced stage AD mice.
Liu and colleagues believe that because the loss of neuronal connections in brain regions critical for memory function is major hallmark of Alzheimer's Disease, preventing those losses can lead to new treatment options. In earlier studies, they determined the principle for controlling the density and plasticity of connections (synapses) between neurons in the hippocampus, the brain region that processes memory. Those studies revealed that the elevation of brain magnesium can selectively reduce background calcium within synapses and thereby enhance synaptic plasticity and density. Further work by Liu and colleagues revealed that elevating magnesium can reverse memory decline in aging rats.
The team's new study builds on those findings and sheds light on the mechanism by which increased magnesium levels may act to protect the brain from neurodegeneration. To explore the protective mechanism, they investigated major signaling pathways critical for synapse function and memory formation. They found that elevated ABeta leads to widespread activation of calcium-dependent signaling molecules that contribute to neuronal degeneration. The activation of these molecules dampens the activity of proteins that are critical for synapse remodeling and memory function – effects that the researchers discovered can be overcome with Magtein therapy.
Magceutics plans to launch a clinical trial in conjunction with Stanford University later this year to determine whether Magtein can reverse memory decline for human patients with Alzheimer's Disease.
Source: "Elevation of Brain Magnesium Prevents and Reverses Cognitive Deficits and Synaptic Loss in Alzheimer's Disease Mouse Model" Wei Li, Jia Yu, Yong Liu, Xiaojie Huang, Nashat Abumaria, Ying Zhu, Xian Huang, Wenxiang Xiong, Chi Ren, Xian-Guo Liu, Dehua Chui, and Guosong Liu in Journal of Neuroscience, 33(19), 8423-8441, published May 8, 2013.
por Fisio » Mié, 16 Oct 2013, 20:26